{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Grund M"],"funding":["NIGMS NIH HHS","NIH HHS"],"pagination":["1177650"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10399622"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14"],"pubmed_abstract":["<i>Burkholderia pseudomallei</i> is a gram-negative bacterium that is the etiological agent of the tropical disease melioidosis. Currently, there is no licensed vaccine for melioidosis, but numerous candidates are being tested for protective efficacy and characterization of the elicited immune response. Our lab has previously reported the immunogenicity of a Bucl8-protein-based peptide antigen, designated L1-CRM<sub>197</sub> (Cross-reacting material 197). When given subcutaneously, this vaccine formulation promoted a strong Th2 (IgG1) antibody response, however immunization did not protect from death. In this study, we hypothesized that an intranasally administered L1-CRM<sub>197</sub> vaccine would induce protective mucosal immunity. To evaluate vaccine efficacy, we developed a surrogate"],"journal":["Frontiers in immunology"],"pubmed_title":["Intranasal immunization with a Bucl8-based vaccine ameliorates bacterial burden and pathological inflammation, and promotes an IgG2a/b dominant response in an outbred mouse model of <i>Burkholderia</i> infection."],"pmcid":["PMC10399622"],"funding_grant_id":["P20 GM144230","S10 OD016165","P20 GM103434","P30 GM103488","U54 GM104942"],"pubmed_authors":["Lukomski S","Grund M","Choi SJ","Powell L"],"additional_accession":[]},"is_claimable":false,"name":"Intranasal immunization with a Bucl8-based vaccine ameliorates bacterial burden and pathological inflammation, and promotes an IgG2a/b dominant response in an outbred mouse model of <i>Burkholderia</i> infection.","description":"<i>Burkholderia pseudomallei</i> is a gram-negative bacterium that is the etiological agent of the tropical disease melioidosis. Currently, there is no licensed vaccine for melioidosis, but numerous candidates are being tested for protective efficacy and characterization of the elicited immune response. Our lab has previously reported the immunogenicity of a Bucl8-protein-based peptide antigen, designated L1-CRM<sub>197</sub> (Cross-reacting material 197). When given subcutaneously, this vaccine formulation promoted a strong Th2 (IgG1) antibody response, however immunization did not protect from death. In this study, we hypothesized that an intranasally administered L1-CRM<sub>197</sub> vaccine would induce protective mucosal immunity. To evaluate vaccine efficacy, we developed a surrogate","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-04T09:24:34.209Z","creation":"2025-04-04T09:24:34.209Z"},"accession":"S-EPMC10399622","cross_references":{"pubmed":["37545515"],"doi":["10.3389/fimmu.2023.1177650"]}}